Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide vs glimepiride in type 2 diabetes (OAM-naive or low-dose OAM)
CTR20131583Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of dulaglutide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Nov 2014; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20131583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131583.